{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:02:21Z","timestamp":1789578141259,"version":"build-2803163510"},"reference-count":28,"publisher":"American Society of Hematology","issue":"7","license":[{"start":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T00:00:00Z","timestamp":1707091200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,4,9]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>The phase 3 ASPEN trial (NCT03053440) compared Bruton tyrosine kinase inhibitors (BTKis), zanubrutinib and ibrutinib, in patients with Waldenstr\u00f6m macroglobulinemia (WM). Post-hoc biomarker analysis was performed using next-generation sequencing on pretreatment bone marrow samples from 98 patients treated with zanubrutinib and 92 patients treated with ibrutinib with mutated (MUT) MYD88 and 20 patients with wild-type (WT) MYD88 treated with zanubrutinib. Of 329 mutations in 52 genes, mutations in CXCR4 (25.7%), TP53 (24.8%), ARID1A (15.7%), and TERT (9.0%) were most common. TP53MUT, ARID1AMUT, and TERTMUT were associated with higher rates of CXCR4MUT (P\u00a0&amp;lt; .05). Patients with CXCR4MUT (frameshift or nonsense [NS] mutations) had lower very good partial response (VGPR) and complete response rates (CR; 17.0% vs 37.2%, P\u00a0= .020) and longer time to response (11.1 vs 8.4\u00a0months) than patients with CXCR4WT treated with BTKis. CXCR4NS was associated with inferior progression-free survival (PFS; hazard ratio [HR], 3.39; P\u00a0= .017) in patients treated with ibrutinib but not in those treated with zanubrutinib (HR, 0.67; P\u00a0= .598), but VGPR + CR rates were similar between treatment groups (14.3% vs 15.4%). Compared with ibrutinib, patients with CXCR4NS treated with zanubrutinib had a favorable major response rate (MRR; 85.7% vs 53.8%; P\u00a0= .09) and PFS (HR, 0.30; P\u00a0= .093). In patients with TP53MUT, significantly lower MRRs were observed for patients treated with ibrutinib (63.6% vs 85.7%; P\u00a0= .04) but not for those treated with zanubrutinib (80.8% vs 81.9%; P\u00a0= .978). In TP53MUT, compared with ibrutinib, patients treated with zanubrutinib had higher VGPR and CR (34.6% vs 13.6%; P\u00a0&amp;lt; .05), numerically improved MRR (80.8% vs 63.6%; P\u00a0= .11), and longer PFS (not reached vs 44.2\u00a0months; HR, 0.66; P\u00a0= .37). Collectively, patients with WM with CXCR4MUT or TP53MUT had worse prognosis compared with patients with WT alleles, and zanubrutinib led to better clinical outcomes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023010906","type":"journal-article","created":{"date-parts":[[2024,2,5]],"date-time":"2024-02-05T20:14:46Z","timestamp":1707164086000},"page":"1639-1650","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":36,"title":["Biomarker analysis of the ASPEN study comparing zanubrutinib with ibrutinib for patients with Waldenstr\u00f6m macroglobulinemia"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"first","affiliation":[{"name":"1Department of Haematology, Alfred Hospital and Centre for Blood Diseases, Monash University, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Opat","sequence":"additional","affiliation":[{"name":"2Department of Haematology, Monash Health and Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"D'Sa","sequence":"additional","affiliation":[{"name":"3Centre for Waldenstr\u00f6m\u2019s Macroglobulinemia and Associated Disorders, University College London Hospital Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1879-8084","authenticated-orcid":false,"given":"Wojciech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"4Department of Clinical Oncology, Maria Sklodowska-Curie National Institute of Oncology, Krakow, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Peng","family":"Lee","sequence":"additional","affiliation":[{"name":"5Department of Haematology, Flinders Medical Centre, Adelaide, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin","family":"Cull","sequence":"additional","affiliation":[{"name":"6Department of Haematology, Sir Charles Gairdner Hospital, University of Western Australia, Perth, WA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger G.","family":"Owen","sequence":"additional","affiliation":[{"name":"7Haematological Malignancy Diagnostic Service, St James University Hospital, Leeds, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Marlton","sequence":"additional","affiliation":[{"name":"8Department of Haematology, Princess Alexandra Hospital and University of Queensland, Brisbane, QLD, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn E.","family":"Wahlin","sequence":"additional","affiliation":[{"name":"9Department of Hematology, Karolinska Universitetssjukhuset and Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4120-2787","authenticated-orcid":false,"given":"Ram\u00f3n","family":"Garc\u00eda-Sanz","sequence":"additional","affiliation":[{"name":"10Department of Hematology, Hospital Universitario de Salamanca, Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"McCarthy","sequence":"additional","affiliation":[{"name":"11Department of Haematology, Royal Bournemouth and Christchurch Hospital, Bournemouth, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1928-2098","authenticated-orcid":false,"given":"Stephen","family":"Mulligan","sequence":"additional","affiliation":[{"name":"12Department of Haematology, Royal North Shore Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[{"name":"13Department of Hematology, Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9490-7532","authenticated-orcid":false,"given":"Jorge J.","family":"Castillo","sequence":"additional","affiliation":[{"name":"14Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Czy\u017c","sequence":"additional","affiliation":[{"name":"15Department of Hematology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toru\u0144, Bydgoszcz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-9255","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez De Larrea","sequence":"additional","affiliation":[{"name":"16Amyloidosis and Myeloma Unit, Department of Hematology, Hospital Cl\u00ednic de Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Belada","sequence":"additional","affiliation":[{"name":"17Department of Internal Medicine \u2013 Haematology, University Hospital and Faculty of Medicine, Hradec Kr\u00e1lov\u00e9, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Libby","sequence":"additional","affiliation":[{"name":"18Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Matous","sequence":"additional","affiliation":[{"name":"19Colorado Blood Cancer Institute, Denver, CO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Motta","sequence":"additional","affiliation":[{"name":"20Department of Hematology, AO Spedali Civili di Brescia, Lombardia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5292-8298","authenticated-orcid":false,"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[{"name":"21Department of Hematology\/Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[{"name":"22U.O. Ematologia, Dipartimento Oncologia e Ematologia, Ospedale Civile Santa Maria delle Croci, AUSL Ravenna, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Trn\u011bn\u00fd","sequence":"additional","affiliation":[{"name":"23V\u0161eobecn\u00e1 fakultn\u00ed nemocnice v Praze, Prague, Czechia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3139-8379","authenticated-orcid":false,"given":"Monique C.","family":"Minnema","sequence":"additional","affiliation":[{"name":"24Department of Hematology, University Medical Center Utrecht, Utrecht, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Buske","sequence":"additional","affiliation":[{"name":"25Comprehensive Cancer Center Ulm, Universit\u00e4tsklinikum Ulm, Ulm, Baden-W\u00fcrttemberg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Leblond","sequence":"additional","affiliation":[{"name":"26Service d'H\u00e9matologie Clinique, Sorbonne University, Piti\u00e9 Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6393-6154","authenticated-orcid":false,"given":"Steven P.","family":"Treon","sequence":"additional","affiliation":[{"name":"14Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8009-4593","authenticated-orcid":false,"given":"Judith","family":"Trotman","sequence":"additional","affiliation":[{"name":"27Department of Hematology, Concord Repatriation General Hospital, Sydney, NSW, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binghao","family":"Wu","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Yu","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Shen","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wai Y.","family":"Chan","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Schneider","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather","family":"Allewelt","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Cohen","sequence":"additional","affiliation":[{"name":"28BeiGene USA, Inc, San Mateo, CA"},{"name":"29BeiGene Co, Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[{"name":"30Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,3,28]]},"reference":[{"issue":"2","key":"2024040516355261800_bib1","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/ajh.25292","article-title":"Waldenstr\u00f6m macroglobulinemia: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Gertz","year":"2019","journal-title":"Am J Hematol"},{"issue":"1","key":"2024040516355261800_bib2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12943-018-0779-z","article-title":"Role of Bruton\u2019s tyrosine kinase in B cells and malignancies","volume":"17","author":"Pal Singh","year":"2018","journal-title":"Mol Cancer"},{"issue":"11","key":"2024040516355261800_bib3","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The genomic landscape of Waldenstr\u00f6m macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"issue":"7","key":"2024040516355261800_bib4","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A\u00a0mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstr\u00f6m macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"issue":"2","key":"2024040516355261800_bib5","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m\u2019s macroglobulinema: chances and challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"issue":"18","key":"2024040516355261800_bib6","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstr\u00f6m macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"issue":"15","key":"2024040516355261800_bib7","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in previously treated Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024040516355261800_bib8","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2019.1649132","article-title":"CXCR4 mutations affect presentation and outcomes in patients with Waldenstr\u00f6m macroglobulinemia: a systematic review","volume":"12","author":"Castillo","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2024040516355261800_bib9","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP53 mutations are associated with mutated MYD88 and CXCR4, and confer an adverse outcome in Waldenstr\u00f6m macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br J Haematol"},{"issue":"20","key":"2024040516355261800_bib10","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 mutation and its prognostic significance in Waldenstr\u00f6m's macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2024040516355261800_bib11","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","article-title":"Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenstr\u00f6m macroglobulinemia","volume":"23","author":"Wang","year":"2021","journal-title":"Neoplasia"},{"issue":"23","key":"2024040516355261800_bib12","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.1182\/bloodadvances.2020003010","article-title":"Zanubrutinib for the treatment of MYD88 wild-type Waldenstr\u00f6m macroglobulinemia: a substudy of the phase 3 ASPEN trial","volume":"4","author":"Dimopoulos","year":"2020","journal-title":"Blood Adv"},{"issue":"18","key":"2024040516355261800_bib13","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1182\/blood.2020006449","article-title":"Zanubrutinib for the treatment of patients with Waldenstr\u00f6m macroglobulinemia: 3 years of follow-up","volume":"136","author":"Trotman","year":"2020","journal-title":"Blood"},{"issue":"6","key":"2024040516355261800_bib14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenstr\u00f6m macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"18","key":"2024040516355261800_bib15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1182\/blood-2017-01-761726","article-title":"Acquired mutations associated with ibrutinib resistance in Waldenstr\u00f6m macroglobulinemia","volume":"129","author":"Xu","year":"2017","journal-title":"Blood"},{"issue":"18","key":"2024040516355261800_bib16","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1182\/blood-2017-10-811752","article-title":"BTKCys481Ser drives ibrutinib resistance via ERK1\/2 and protects BTKwild-type MYD88-mutated cells by a paracrine mechanism","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2024040516355261800_bib17","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1111\/bjh.16463","article-title":"Genomic evolution of ibrutinib-resistant clones in Waldenstr\u00f6m macroglobulinaemia","volume":"189","author":"Jim\u00e9nez","year":"2020","journal-title":"Br J Haematol"},{"issue":"9","key":"2024040516355261800_bib18","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2018.190181","article-title":"MYD88 mutated and wild-type Waldenstr\u00f6m\u2019s macroglobulinemia: characterization of chromosome 6q gene losses and their mutual exclusivity with mutations in CXCR4","volume":"103","author":"Guerrera","year":"2018","journal-title":"Haematologica"},{"issue":"18","key":"2024040516355261800_bib19","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A\u00a0randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024040516355261800_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00011","article-title":"OncoKB: a precision oncology knowledge base","volume":"2017","author":"Chakravarty","year":"2017","journal-title":"JCO Precis Oncol"},{"issue":"7571","key":"2024040516355261800_bib21","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nature15393","article-title":"A\u00a0global reference for human genetic variation","volume":"526","author":"Auton","year":"2015","journal-title":"Nature"},{"issue":"D1","key":"2024040516355261800_bib22","doi-asserted-by":"crossref","first-page":"D840","DOI":"10.1093\/nar\/gkw971","article-title":"The ExAC browser: displaying reference data information from over 60 000 exomes","volume":"45","author":"Karczewski","year":"2017","journal-title":"Nucleic Acids Res"},{"issue":"7809","key":"2024040516355261800_bib23","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","article-title":"The mutational constraint spectrum quantified from variation in 141,456 humans","volume":"581","author":"Karczewski","year":"2020","journal-title":"Nature"},{"issue":"22","key":"2024040516355261800_bib24","doi-asserted-by":"crossref","first-page":"3216","DOI":"10.1093\/bioinformatics\/btr540","article-title":"Kaviar: an accessible system for testing SNV novelty","volume":"27","author":"Glusman","year":"2011","journal-title":"Bioinformatics"},{"issue":"2","key":"2024040516355261800_bib25","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response assessment in Waldenstr\u00f6m macroglobulinaemia: update from the VIth International Workshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"2024040516355261800_bib26","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 mutation subtypes impact response and survival outcomes in patients with Waldenstr\u00f6m macroglobulinaemia treated with ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br J Haematol"},{"issue":"5","key":"2024040516355261800_bib27","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br J Haematol"},{"issue":"11","key":"2024040516355261800_bib28","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.2019001160","article-title":"Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL","volume":"134","author":"Tam","year":"2019","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1639\/2220798\/blooda_adv-2023-010906-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/7\/1639\/2220798\/blooda_adv-2023-010906-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T16:36:13Z","timestamp":1712334973000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/7\/1639\/514812\/Biomarker-analysis-of-the-ASPEN-study-comparing"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,28]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,4,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023010906","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,28]]}}}